- Details
- Oliver Sartor interviews William Kevin Kelly about findings on AMG 509 (Xaluritamig), a STEAP1-targeted T-cell engager for advanced prostate cancer. Dr. Kelly discusses the drug's mechanism, dosing optimization, and efficacy in heavily pretreated patients. He highlights the manageable cytokine release syndrome and the need to address musculoskeletal side effects. The conversation covers impressive...
|
- Details
- Himisha Beltran discuses DLL3, a promising target for neuroendocrine prostate cancer treatment. Dr. Beltran explains that DLL3 is highly expressed in neuroendocrine and small cell prostate cancers, making it an attractive therapeutic target. She reviews recent clinical trials of DLL3-targeted T-cell engagers, including Tarlatamab and MK-6070, highlighting their potential efficacy in treating neuro...
|
- Details
- Oliver Sartor hosts Jake Berchuck to discuss a novel epigenomic liquid biopsy platform for determining PSMA expression in prostate cancer. Dr. Berchuck explains how the assay analyzes cell-free DNA to infer tumor PSMA expression, showing strong correlation with PSMA PET scan results. They explore the potential of this technology to provide real-time, non-invasive monitoring of tumor drug target ex...
|
- Details
- Oliver Sartor and Ken Herrmann discuss the current state and future directions of PSMA ligand therapy in prostate cancer treatment. Dr. Herrmann presents recent findings from various clinical trials, including PSMAfore and ENZA-p, which explore the use of lutetium-PSMA therapy in different stages of prostate cancer. They examine the potential of combining lutetium-PSMA with other treatments like e...
|
- Details
- Nicholas James and Gerhardt Attard discuss findings from the STAMPEDE trial, focusing on molecular profiling of prostate cancer tumors. They explore the use of the Decipher® genomic classifier as a prognostic and predictive tool for treatment decisions in metastatic prostate cancer. The conversation covers the test's ability to identify patients who are likely to benefit from abiraterone and, more...
|
- Details
- Oliver Sartor host Dana Rathkopf for a discussion on BMS-986365, a novel androgen receptor ligand-directed degrader for prostate cancer treatment. Dr. Rathkopf discusses the drug's unique dual mechanism of action, which both degrades and competitively inhibits the androgen receptor. She presents data from the phase I/II trial, highlighting the drug's efficacy, particularly in patients without prio...
|
- Details
- Neeraj Agarwal discusses a post-hoc analysis of the TALAPRO-2 Phase III study, which evaluates the efficacy of talazoparib and enzalutamide in metastatic castrate-resistant prostate cancer patients with prior ARPI or docetaxel treatment. The analysis shows promising results for the combination therapy, particularly in patients with HRR-deficient tumors. Dr. Agarwal emphasizes the potential benefit...
|
- Details
- Oliver Sartor interviews Neeraj Agarwal about the CONTACT-02 trial, which compares cabozantinib plus atezolizumab to second ARPI in metastatic castrate-resistant prostate cancer patients. Dr. Agarwal presents the final overall survival results from the study, which shows improved progression-free survival with the combination therapy, particularly in patients with liver or bone metastasis. While o...
|
- Details
- In this conversation, Fred Saad discusses the PEACE-3 trial results. The study compares enzalutamide plus radium-223 versus enzalutamide alone in metastatic castration-resistant prostate cancer patients with bone metastases. Dr. Saad discusses the trial's design, highlighting significant improvements in radiographic progression-free survival and overall survival with the combination therapy. They...
|
- Details
- Nicholas James and Minal Padden-Modi discuss the STAMPEDE2 trial Arm P, which examines the use of upfront accelerated lutetium-PSMA-617 in metastatic hormone-sensitive prostate cancer. Dr. Padden-Modi outlines the trial design, which randomizes patients to standard of care with or without lutetium-PSMA-617, administered in an accelerated schedule. The trial includes an imaging sub-study to evaluat...
|
